Skip to content
GERICLINICS

GeriQBank · Paper IV · Q3

Newer Insulin Analogues

High YieldAsked ×27-mark note
Topic
Diabetes & Endocrinology
Chapter
Endocrine, Metabolic, Renal & Genitourinary Systems
Years asked
Not recorded in the source
Frequency
Set 2× in Paper IV (2009–2025)

As set in the university paper

  • Newer insulin analogues — onset and duration of action, and their advantage over the older insulins.

    Paper IV · Endocrine & Metabolic · asked ×2 · 7-mark note · see in paper list

Answer framework

  1. Concept and rationale — altered sequence or acylation; "longer, faster, easier"; the hexamer
  2. Rapid-acting analogues — lispro, aspart, glulisine; timing; comparison with regular insulin
  3. Ultra-rapid formulations — faster aspart, lispro-aabc, inhaled insulin
  4. Long-acting analogues — glargine, detemir, degludec; glargine U300 in older people
  5. Combinations and practical use — IDegAsp, premixes, basal insulin with a GLP-1 agonist; simplification and targets; hypoglycaemia; biosimilars
  6. Recent updates — weekly insulins (icodec, efsitora), caution in type 1, implications for older people, ADA 2026, CGM targets

An exam answer plan drawn from the detailed answer below. Use it to attempt the question first.

Detailed answer

Pro · free in beta
Attempt it firstOutline your answer as a 7-mark note before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer

Short revision answer

  • Insulin analogues alter the amino-acid sequence or add acylation to change absorption, giving faster prandial action or flatter basal profiles ("longer, faster, easier"). Human insulin is a hexamer that must dissociate before it is absorbed; analogues manipulate this step.
  • Rapid analogues (lispro, aspart, glulisine): onset 5–15 minutes, duration 4–6 hours. They can be given right before or even after a meal — useful with variable appetite, dysphagia or dementia. Regular insulin starts in 30 minutes and lasts 5–8 hours, risking late hypoglycaemia.
  • Ultra-rapid forms: faster aspart (niacinamide + L-arginine), lispro-aabc (treprostinil + citrate) and inhaled insulin (onset about 12 minutes; contraindicated in asthma and COPD).
  • Long-acting analogues (glargine U100 and U300, detemir, degludec) give flat 24-hour cover with less nocturnal hypoglycaemia than NPH. Degludec forms multihexamers, lasts over 42 hours and allows flexible timing. Glargine U300 causes less nocturnal hypoglycaemia than U100 in people over 65, and long-acting analogues are the preferred starting insulin in older adults.
  • Combinations: IDegAsp (the only basal insulin that can be mixed with a rapid analogue), premixed analogues for twice-daily regimens, and fixed-ratio basal insulin plus a GLP-1 agonist (IDegLira, iGlarLixi) to cut injections, weight gain and hypoglycaemia.
  • In older adults, simplify (a twice-daily premix or long-acting analogue); the HbA1c target at age 70 and over is about 7.0–7.5%. Insulin carries more hypoglycaemia risk than most oral agents, and sliding scales should be avoided in hospital. Biosimilars make analogues affordable in India.
  • Weekly basal insulins (icodec, efsitora) are non-inferior to daily insulin in type 2 diabetes; QWINT-1 had about 40% fewer significant hypoglycaemic events than glargine. In type 1 diabetes they cause more hypoglycaemia.
  • Weekly dosing cuts injections from 365 to 52 a year — valuable in care homes and dementia — but a dosing error persists for days. ADA 2026: simplify regimens, prefer analogues over NPH, and pair insulin with CGM (time in range 70–180 mg/dL above 50–70%, time below range under 1%).

Condensed by GeriClinics from the detailed answer below, with no new facts added.

A. Concept and Rationale

1.

Insulin analogues are recombinant insulins with altered amino-acid sequence or acylation that change absorption kinetics, producing either faster prandial action or flatter, longer basal profiles.

2.

The direction of insulin development has been to make insulin “longer, faster and easier”.

3.

Human insulin exists as a hexamer in the vial and must dissociate to dimers and monomers before absorption — the step that analogues manipulate.

B. Rapid-Acting (Bolus) Analogues

4.

Insulin lispro, aspart and glulisine have one or two amino-acid changes that weaken self-association; onset 5–15 minutes, peak earlier and higher, duration 4–6 hours.

5.

They can be injected immediately before or even after a meal — a major advantage in older people with variable appetite, dysphagia or dementia.

6.

Regular human insulin, by contrast, starts in 30 minutes and lasts 5–8 hours, causing late post-prandial hypoglycaemia.

C. Ultra-Rapid Formulations

7.

Faster aspart (Fiasp) contains niacinamide and L-arginine, accelerating monomer formation and capillary permeation, with greater early glucose lowering.

8.

Lispro-aabc (LY900014/URLi) contains treprostinil (local vasodilatation) and citrate (increased vascular permeability), speeding absorption.

9.

Inhaled insulin (Afrezza) uses a dry powder on fumaryl diketopiperazine microparticles, with onset about 12 minutes and offset by 90–180 minutes; contraindicated in asthma and COPD.

D. Long-Acting (Basal) Analogues

10.

Insulin glargine (U100 and U300), detemir and degludec (U100/U200) provide flat 24-hour basal cover with less nocturnal hypoglycaemia than NPH.

11.

Degludec is a detemir-derived molecule with B30 threonine deleted and a 16-carbon fatty diacid attached to B29 lysine via a glutamic acid spacer, forming subcutaneous multihexamers; duration exceeds 42 hours and permits flexible timing.

12.

Glargine U300 is as effective as U100 in patients over 65 with less nocturnal hypoglycaemia — hence long-acting analogues are the preferred starting insulin in older adults.

E. Combinations and Practical Use

13.

Co-formulations: IDegAsp (degludec/aspart, Ryzodeg) — the only basal insulin that can be mixed with a rapid analogue in one injection; premixed analogues (Humalog Mix 25/50, NovoMix 30) suit twice-daily regimens.

14.

Fixed-ratio basal insulin + GLP-1 combinations — IDegLira (degludec/liraglutide) and iGlarLixi (glargine/lixisenatide) — reduce injections, weight gain and hypoglycaemia.

15.

In older adults with type 1 diabetes or those unable to manage basal-bolus regimens, twice-daily premixed analogue or twice-daily long-acting analogue is a reasonable simplification; HbA1c target at age ≥70 is about 7.0–7.5%.

16.

Insulin therapy carries a higher hypoglycaemia risk than most oral agents in older adults; sliding-scale insulin should not be used in hospital.

17.

Biosimilar glargine and aspart have made analogue therapy affordable in India, an important consideration for pensioners and AB-PMJAY beneficiaries.

Latest Updates (2023–Present)

Once-weekly basal insulins are the major advance. Insulin icodec (ONWARDS 1–6) and insulin efsitora alfa (QWINT 1–5) achieved non-inferior HbA1c reduction versus daily glargine or degludec in type 2 diabetes. QWINT-1 (NEJM, 2025) used a fixed-dose escalation and showed about 40% fewer clinically significant or severe hypoglycaemic events than glargine in insulin-naïve type 2 diabetes; QWINT-3 and QWINT-4 (Lancet, 2025) confirmed non-inferiority in basal-experienced and basal-bolus patients.

In type 1 diabetes, weekly insulins are less favourable — QWINT-5 showed higher rates of level 2/3 hypoglycaemia with efsitora versus degludec, and ONWARDS 6 raised similar concerns for icodec. Practical implication for geriatrics: weekly insulin reduces injections from 365 to 52 per year, potentially transforming care in care homes, in patients dependent on visiting nurses or family carers, and in those with dementia — but requires care with dose changes, since the effect of an error persists for days. ADA Standards of Care 2026 emphasise simplification of complex insulin regimens in older adults, preferential use of analogues over NPH and human regular insulin, and pairing insulin therapy with continuous glucose monitoring to detect asymptomatic nocturnal hypoglycaemia.

Continuous glucose monitoring is now recommended for older insulin-treated adults, with time-in-range 70–180 mg/dL >50–70% and time-below-range <1% as the geriatric targets, replacing HbA1c-only assessment.

Current Practice Update

Aspect Textbook Position Current Evidence / Guideline Basal insulin frequency Once or twice daily Once-weekly icodec and efsitora non-inferior in type 2 diabetes Weekly insulin in type 1 DM Not applicable Higher hypoglycaemia — not recommended as a routine option Choice of basal insulin in elderly Analogue preferred over NPH Unchanged and strengthened; NPH and human regular discouraged Monitoring HbA1c and capillary glucose CGM with time-in-range metrics, especially for hypoglycaemia detection Regimen complexity Individualise Formal simplification/de-intensification protocols recommended Exam One-Liners Rapid analogues — lispro, aspart, glulisine; onset 5–15 min, may be given after meals. Faster aspart = niacinamide + arginine; lispro-aabc = treprostinil + citrate.

Degludec — ultra-long, multihexamer formation, flexible dosing, mixable with aspart. Glargine U300 causes less nocturnal hypoglycaemia than U100 in those over 65.

IDegLira and iGlarLixi — fixed-ratio basal insulin plus GLP-1 agonist.

Weekly insulins work in type 2 but not safely in type 1.

How was your recall?

Rating marks the question complete. “Need another pass” also adds it to your bookmarks.

References

Spotted an error or something out of date?Report a problem with this page